TEVA
Teva Pharma Industries Ltd ADRNYSE
Healthcare • Drug Manufacturers - Specialty & Generic
Factor tilt: Large-Cap Blend
$42.61+1.99%
Close Nov 6, 2026
- Market cap
- $50.32B
- 1 month
- +8.6%
- 3 months
- +17.9%
- 1 year
- +73.2%
- 52-week range
- $23.97$42.61
- Dividend, last 12 mo
- None in the last year
- Last ex-date
- Nov 27, 2017 · $0.085
- Next-quarter EPS estimate
- $0.72Quarter to Sep 30, 2026 · 12 analysts · revenue $4.23B · +0.7% in 30d
- Short interest
- 2.6% of float28.1M shares · settled Oct 15, 2026 · -6.0% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $17.31B
- Net income
- $706M
- Free cash flow
- $1.35B
- Book value
- $7.76B
- Total debt
- $16.87B
- P/E
- 71.3×
- Price / sales
- 2.9×
- Price / book
- 6.5×
- FCF yield
- +2.7%
- Net margin
- +4.1%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Teva Pharma Industries Ltd ADR
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
Read more
It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
- Website
- tevapharm.com
- Headquarters
- Tel Aviv-Yafo, Israel
- Employees
- 31,173
- Listed
- Mar 26, 1990
- Fiscal year ends
- December
Company profile from EODHD, stored Nov 5, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Jul 29, 2026 | $4.1B | -0.8% | 52.0% | $149.0M | -$576.0M |
| Mar 2026filed Apr 29, 2026 | $4.0B | +2.3% | 49.5% | $652.0M | $369.0M |
| Dec 2025filed Feb 3, 2026 | $4.7B | +11.4% | 56.4% | $300.0M | $480.0M |
| Sep 2025filed Nov 5, 2025 | $4.5B | +3.4% | 51.4% | $882.0M | $433.0M |
| Jun 2025filed Jul 30, 2025 | $4.2B | +0.3% | 50.3% | $455.0M | $282.0M |
| Mar 2025filed May 7, 2025 | $3.9B | +1.9% | 48.2% | $519.0M | $214.0M |
| Dec 2024filed Feb 5, 2025 | $4.2B | -5.1% | 50.1% | -$29.0M | -$217.0M |
| Sep 2024filed Nov 6, 2024 | $4.3B | +12.5% | 49.6% | -$51.0M | -$437.0M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Feb 3, 2026 | $17.3B | +4.3% | 51.8% | $2.2B | $1.4B |
| Dec 2024filed Feb 5, 2025 | $16.5B | +4.4% | 48.7% | -$303.0M | -$1.6B |
| Dec 2023filed Jan 31, 2024 | $15.8B | +6.2% | 48.2% | $433.0M | -$559.0M |
| Dec 2022filed Feb 10, 2023 | $14.9B | -6.0% | 46.7% | -$2.2B | -$2.4B |
| Dec 2021filed Feb 9, 2022 | $15.9B | -4.7% | 47.8% | $1.7B | $417.0M |
| Dec 2020filed Feb 10, 2021 | $16.7B | -1.4% | 46.4% | -$3.6B | -$4.0B |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched TEVA. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
28,070,513 shares short
-1,778,292 shares (-6%) vs Sep 30, 2026
2.6% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
29,848,805 shares short
-1,629,509 shares (-5.2%) vs Sep 15, 2026
2.7% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
31,478,314 shares short
-6,135,939 shares (-16.3%) vs Aug 31, 2026
2.9% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
37,614,253 shares short
+1,943,389 shares (+5.4%) vs Aug 14, 2026
3.5% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
35,670,864 shares short
+1,349,884 shares (+3.9%) vs Jul 31, 2026
3.3% of the stored float. Published Aug 25, 2026.
Settlement Jul 31, 2026
34,320,980 shares short
+1,579,969 shares (+4.8%) vs Jul 15, 2026
3.2% of the stored float. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind TEVA’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
The newest stored ex-date is Nov 27, 2017. These are historical records; a current dividend schedule is unavailable.
USD 0.085 per share
Ex-dividend date: Nov 27, 2017
Recorded pay date: Dec 12, 2017 (past date)
Cash dividend · Polygon event record
USD 0.085 per share
Ex-dividend date: Aug 25, 2017
Recorded pay date: Sep 14, 2017 (past date)
Cash dividend · Polygon event record
USD 0.34 per share
Ex-dividend date: Jun 1, 2017
Recorded pay date: Jun 22, 2017 (past date)
Cash dividend · Polygon event record
USD 0.34 per share
Ex-dividend date: Feb 28, 2017
Recorded pay date: Mar 20, 2017 (past date)
Cash dividend · Polygon event record
USD 0.34 per share
Ex-dividend date: Dec 1, 2016
Recorded pay date: Dec 20, 2016 (past date)
Cash dividend · Polygon event record
USD 0.34 per share
Ex-dividend date: Aug 18, 2016
Recorded pay date: Sep 8, 2016 (past date)
Cash dividend · Polygon event record
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
2 for 1 · forward split
Effective Jul 1, 2004
Each 1 pre-split share becomes 2 post-split shares.
Source: EODHD
2 for 1 · forward split
Effective Dec 6, 2002
Each 1 pre-split share becomes 2 post-split shares.
Source: EODHD
2 for 1 · forward split
Effective Feb 23, 2000
Each 1 pre-split share becomes 2 post-split shares.
Source: EODHD
2 for 1 · forward split
Effective Apr 14, 1993
Each 1 pre-split share becomes 2 post-split shares.
Source: EODHD
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if TEVA is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
118 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Oct 30, 2026
Smart-money 13F trend: distributing (light)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: bearish
Last trade: sell 1 days ago
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 2
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
679 filers reported a long position in TEVA for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
54.3%
of the 733.7M shares 13-F filers reported
Moves vs Q1 2026
6 added3 trimmed
1 not comparable
Net shares held
-1.5%
across the 9 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | $2.2B · 63.9M shares | 63.9M | -1.9% |
| 2 | Harel Insurance Investments & Financial Services Ltd. | $1.6B · 48.1M shares | 48.1M | +4.7% |
| 3 | Phoenix Financial Ltd. | $1.5B · 42.9M shares | 42.9M | +0.4% |
| 4 | WCM INVESTMENT MANAGEMENT, LLC | $1.4B · 41.3M shares | 41.3M | +1.2% |
| 5 | Clal Insurance Enterprises Holdings Ltd | $1.4B · 40.6M shares | 40.6M | +5.6% |
| 6 | MENORA MIVTACHIM HOLDINGS LTD. | $1.4B · 39.9M shares | 39.9M | +0.6% |
| 7 | Migdal Insurance & Financial Holdings Ltd. | $1.3B · 38.9M shares | 38.9M | +2.7% |
| 8 | NORGES BANK | $1.1B · 32.3M shares | 32.3M | — |
| 9 | FMR LLC | $1B · 30.3M shares | 30.3M | -8.7% |
| 10 | Lingotto Investment Management LLP | $684.6M · 20.2M shares | 20.2M | -27.2% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign inGet the Full Analysis for TEVA
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.